Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ATLAS Biolabs is Awarded Certified Service Provider Accreditation from Affymetrix for DMET Analysis

Published: Tuesday, September 25, 2012
Last Updated: Tuesday, September 25, 2012
Bookmark and Share
DMET Plus uses microarray testing to investigate common variations in genes encoding for drug-metabolism enzymes and drug transporters, and to identify their impact on the individual metabolic capacity.

ATLAS Biolabs announces its accreditation as a certified Affymetrix DMET™ Service Provider, offering the latest DMET™ Plus Solution from Affymetrix. ATLAS Biolabs is the first European Certified Service Provider to offer the DMET technology for use in molecular pharmacogenetics in Germany.

Allelic variants with catalytic activities different from wild-type forms have been identified for an increasing number of drug-metabolizing enzymes and drug transporters. Analyzing the diversity of these proteins has become extremely important in the evaluation of drug toxicity. Thus, genotyping patients with respect to a particular genetic variant helps to avoid adverse drug responses, increase treatment efficacy, and achieve both improved healthcare outcomes and substantial economic benefits.

DMET Plus covers a broad range of 1,936 genetic variants across 231 relevant genes in one assay. Moreover, the test inspires high confidence in results and supports the rapid and comprehensive interpretation of genotyping data. DMET Plus will be useful in the discovery of novel biomarkers resulting from pharmacogenetic associations, as well as in the optimization of drug candidates. DMET could also improve translational and clinical trials by showing the effects of known metabolic pathways in poor drug responders, and confirm metabolic pathway involvement in newly discovered drug-metabolism associations.

“DMET helps translate pharmacogenetics into practice and will take us one step closer to the vision of personalized medicine,” says Patrick Kelly, Director of Sales and Market Development at ATLAS Biolabs. “We are excited to offer our customers this new tool, which opens up the possibility of measuring existing and new metabolic pathways in a cost-effective and very reliable way.”

The DMET™ Plus Solution
DMET Plus from Affymetrix includes (a) a molecular inversion probe (MIP) panel to amplify the precise target DNA of interest; (b) an allele-specific oligonucleotide array providing a single-color readout on Affymetrix’s GeneChip System® 3000 or the GeneChip® System 3000Dx v.2; and (c) the DMET analysis software, which offers both flexibility for user-defined reporting and the most comprehensive translation from genotypic data to star-allele classification and to predicted metabolizer status for the most clinically relevant genes. Assay performance is characterized by >99% average sample-call rates and >99.8% average sample reproducibility, which enables the accurate generation of haplotypes and supports longitudinal and other clinical research studies.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Recruitment of First Patient in Clinical Study
Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Chi-Med Initiates Sulfatinib Phase III Registration Study
Company has initiated SANET-p, a Phase III registration trial of sulfatinib with pancreatic neuroendocrine tumors (“NETs”).
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!